Cheminformatic Discovery of Alternative Pathway C3 Pro-Convertase Inhibitors
替代途径 C3 前转化酶抑制剂的化学信息学发现
基本信息
- 批准号:8877399
- 负责人:
- 金额:$ 18.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAffinityAlternative Complement PathwayAnaphylatoxinsAnti-Inflammatory AgentsAnti-inflammatoryAreaAutoimmunityBindingBiochemicalBiological AssayCell surfaceChemicalsChronicClinicComplementComplement 3bComplement ActivationComplement InactivatorsComplexComputer SimulationDefense MechanismsDevelopmentDiseaseDrug TargetingEventEvolutionFDA approvedFamilyFoundationsFutureGoalsGraft RejectionHealthHumanHuman bodyImmune systemImmunityInflammatoryInflammatory ResponseInterventionInvestigationLaboratoriesLeadLibrariesMalignant NeoplasmsMediatingMedicalMethodologyMethodsModelingModificationNatural SelectionsNatureNeurodegenerative DisordersOutcomePathway interactionsPeptide HydrolasesPharmaceutical PreparationsPlayPopulationPriceProcessProtein ArrayProteinsQuantitative Structure-Activity RelationshipRare DiseasesReperfusion InjuryResearchRoleRouteScientistSepsis SyndromeSeriesSiteSpecificityStagingStaphylococcus aureusStructureStructure-Activity RelationshipSurfaceSystemTestingTherapeuticTherapeutic InterventionValidationVirulenceVirulence FactorsWorkalternative pathway complement C3 convertasebasebiochemical toolsbiomaterial incompatibilitycheminformaticscomplement C3 precursorcomplement systemdriving forceexperienceextracellularhuman diseaseinhibitor/antagonistmembermolecular recognitionnovelnovel strategiespathogenpharmacophoreprotein complexresponsescaffoldscreeningsmall moleculetherapeutic targettool
项目摘要
DESCRIPTION (provided by applicant): Although complement serves as a pillar of the innate immune system, inappropriate or uncontrolled levels of complement activation are a major contributor to a rapidly growing list of human inflammatory diseases. Yet even though therapeutic manipulation of the complement response would be tremendously important in the clinic, only a limited panel of FDA approved drugs and indications exist for specifically targeting
an active component within the complement system. A major factor underlying this dearth of complement-targeted therapeutics is the large size of the proteins and complex nature of the molecular recognition events which underlie complement activity. This has made it very challenging for scientists to identify which specific points are most susceptible for therapeutic intervention. By contrast, the bacterial pathogen Staphylococcus aureus deploys an array of proteins that have been naturally selected and exquisitely optimized during the course of host/pathogen co-evolution to efficiently block fundamental events within the complement cascade - in particular formation of the multi-subunit AP C3 convertase that drives amplification of the complement response. As a consequence, molecules which mimic the activities of staphylococcal virulence proteins hold promise for complement-directed, anti-inflammatory therapeutics. We recently investigated the potential of using novel cheminformatic tools for identifying small molecules that bind the same C3b site as the SCIN family of S. aureus complement inhibitors. Although done on a pilot scale, this work strongly suggested that in silico methods are a viable means of screening for new chemotypes of drug-like compounds that specifically target functionally significant sites on C3b. In this investigation, our goal is to aply the same cheminformatic methods to screen a highly elaborated (~20 million) compound library and to identify small molecules that bind C3b sites with known roles in the initial step of AP C3 convertase formation. This step, which generates a structure known as the AP C3 pro-convertase, is the same point in the pathway that is disrupted by multiple families of secreted S. aureus complement inhibitors (including SCINs). Thus, we believe that formation of the AP C3 pro-convertase is a biologically validated target for pharmacological intervention in the complement-mediated inflammatory response. The research plan described in this application consists of three distinct specific aims. Each aim has a defined outcome that is based upon either preliminary studies directly relevant to this project or our previous experience in using similar methodologies. In the first aim, we will use cheminformatics to identify ~100 hit compounds that are likely binders at one of four target sites on C3b with known roles in AP C3 pro-convertase formation. Then, in the second aim, we will use established biochemical and functional tools to validate ~20 candidates that both bind C3b and inhibit AP activity. In the fina aim, we will use structural comparisons to identify the pharmacophores in these validated candidates and conduct a limited synthetic expansion of our most promising ~ 5 compound series. At the conclusion of this aim, we will have identified a single, non-toxic compound that will serve as our lead inhibitor of AP C3 pro-convertase assembly. As a consequence, this work will lay the foundation for future development of new classes of complement-targeted anti-inflammatory therapeutics.
描述(由申请人提供):尽管补体是先天免疫系统的支柱,但不适当或不受控制的补体激活水平是导致人类炎症性疾病迅速增加的主要因素。然而,尽管补体应答的治疗操作在临床上非常重要,但只有有限的FDA批准的药物和适应症存在特异性靶向
补体系统中的活性成分。补体靶向治疗剂缺乏的主要因素是蛋白质的大尺寸和作为补体活性基础的分子识别事件的复杂性质。这使得科学家们很难确定哪些特定点最容易进行治疗干预。相比之下,细菌病原体金黄色葡萄球菌(Staphylococcus aureus)部署了一系列蛋白质,这些蛋白质在宿主/病原体共进化的过程中已经被天然选择和精细优化,以有效地阻断补体级联中的基本事件-特别是驱动补体应答扩增的多亚基AP C3转化酶的形成。因此,模拟葡萄球菌毒力蛋白活性的分子有望用于补体导向的抗炎治疗。 我们最近研究了使用新的化学信息学工具来鉴定与S的SCIN家族相同的C3 b位点结合的小分子的潜力。金黄色葡萄球菌补体抑制剂。虽然是在中试规模上进行的,但这项工作强烈表明,计算机模拟方法是筛选特异性靶向C3 b上功能重要位点的药物样化合物的新化学型的可行方法。在这项研究中,我们的目标是应用相同的化学信息学方法来筛选高度精细(约2000万)的化合物库,并鉴定在AP C3转化酶形成的初始步骤中结合具有已知作用的C3 b位点的小分子。这一步骤产生了一种称为AP C3前转化酶的结构,是该途径中被多个分泌型S家族破坏的同一点。金黄色葡萄球菌补体抑制剂(包括SCIN)。因此,我们认为AP C3前转化酶的形成是补体介导的炎症反应中药理学干预的生物学验证靶标。 本申请中描述的研究计划包括三个不同的具体目标。每个目标都有一个明确的结果,该结果基于与该项目直接相关的初步研究或我们以前使用类似方法的经验。在第一个目标中,我们将使用化学信息学来鉴定约100种命中化合物,这些化合物可能是C3 b上四个靶位点之一的结合剂,在AP C3前转化酶形成中具有已知的作用。然后,在第二个目标中,我们将使用已建立的生物化学和功能工具来验证约20个既结合C3 b又抑制AP活性的候选物。在最后的目标,我们将使用结构比较,以确定药效团在这些验证的候选人,并进行有限的合成扩展,我们最有前途的~ 5化合物系列。在这个目标的结论,我们将确定一个单一的,无毒的化合物,将作为我们的AP C3前转化酶组装的主要抑制剂。因此,这项工作将为未来开发新的补体靶向抗炎疗法奠定基础。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Quantitative monitoring of two simultaneously binding species using Label-Enhanced surface plasmon resonance.
使用标记增强表面等离子体共振定量监测两个同时结合的物质。
- DOI:10.1016/j.bbrc.2018.02.040
- 发表时间:2018
- 期刊:
- 影响因子:3.1
- 作者:Eng,Lars;Garcia,BrandonL;Geisbrecht,BrianV;Hanning,Anders
- 通讯作者:Hanning,Anders
Identification of a staphylococcal complement inhibitor with broad host specificity in equid Staphylococcus aureus strains.
- DOI:10.1074/jbc.ra117.000599
- 发表时间:2018-03-23
- 期刊:
- 影响因子:0
- 作者:de Jong NWM;Vrieling M;Garcia BL;Koop G;Brettmann M;Aerts PC;Ruyken M;van Strijp JAG;Holmes M;Harrison EM;Geisbrecht BV;Rooijakkers SHM
- 通讯作者:Rooijakkers SHM
Expression, purification, and characterization of a human complement component C3 analog that lacks the C-terminal C345c domain.
缺乏 C 末端 C345c 结构域的人补体成分 C3 类似物的表达、纯化和表征。
- DOI:10.1016/j.jim.2019.07.005
- 发表时间:2019
- 期刊:
- 影响因子:2.2
- 作者:Ramyar,KasraX;Xu,Xin;White,NatalieM;Keightley,Andrew;Geisbrecht,BrianV
- 通讯作者:Geisbrecht,BrianV
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian V Geisbrecht其他文献
Brian V Geisbrecht的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian V Geisbrecht', 18)}}的其他基金
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
- 批准号:
10395608 - 财政年份:2021
- 资助金额:
$ 18.8万 - 项目类别:
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
- 批准号:
10576908 - 财政年份:2021
- 资助金额:
$ 18.8万 - 项目类别:
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
- 批准号:
10166534 - 财政年份:2021
- 资助金额:
$ 18.8万 - 项目类别:
Novel Enzyme Inhibitors in the Immune Evasion Repertoire of Staphylococcus aureus (Equipment Supplement)
金黄色葡萄球菌免疫逃逸的新型酶抑制剂(设备补充)
- 批准号:
10796329 - 财政年份:2021
- 资助金额:
$ 18.8万 - 项目类别:
Structure/Function Studies of LILRs Enabled by a Bacterially-Derived Ligand
由细菌衍生的配体实现的 LILR 的结构/功能研究
- 批准号:
10308089 - 财政年份:2020
- 资助金额:
$ 18.8万 - 项目类别:
Novel Staphylococcal Inhibitors of Neutrophil Granule Enzymes
新型葡萄球菌中性粒细胞颗粒酶抑制剂
- 批准号:
9462166 - 财政年份:2017
- 资助金额:
$ 18.8万 - 项目类别:
Novel Staphylococcal Inhibitors of Neutrophil Granule Enzymes
新型葡萄球菌中性粒细胞颗粒酶抑制剂
- 批准号:
9906231 - 财政年份:2017
- 资助金额:
$ 18.8万 - 项目类别:
Inhibition of the Classical & Lectin Complement Pathways by Staphylococcus aureus Eap
古典的抑制
- 批准号:
8891551 - 财政年份:2015
- 资助金额:
$ 18.8万 - 项目类别:
Cheminformatic Discovery of Alternative Pathway C3 Pro-Convertase Inhibitors
替代途径 C3 前转化酶抑制剂的化学信息学发现
- 批准号:
8772480 - 财政年份:2014
- 资助金额:
$ 18.8万 - 项目类别:
Structure Function Analysis of Staphylococcal Complement Inhibitors
葡萄球菌补体抑制剂的结构功能分析
- 批准号:
7382408 - 财政年份:2008
- 资助金额:
$ 18.8万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 18.8万 - 项目类别:
Research Grant